(MENAFN- Quintile Reports) The Global Dengue Testing Market was estimated at USD 637.90 million in 2026 and is projected to reach USD 1234.3 million by 2035 , reflecting a robust CAGR of 6.82% over the forecast period from 2026 to 2035. The Dengue Testing market report offers a comprehensive and nuanced view of the industry, moving beyond conventional analysis. It provides a thorough examination of the markets dynamics, encompassing a detailed exploration of the factors propelling growth, such as evolving economic conditions, advancements in technology, shifts in regulatory policies, and changes in consumer behavior. Furthermore, the report discusses the projected Compound Annual Growth Rate (CAGR), providing stakeholders with a clear understanding of the market's expected growth trajectory and offering data-driven insights into future market dynamics.
The Dengue Testing market under analysis is characterized by dynamic growth and evolving trends that are reshaping the competitive landscape. With 2025 serving as the base year for this Dengue Testing market study, recent data highlights a significant expansion driven by technological advancements, rising consumer demand, and a growing focus on innovation. Companies are refining their go-to-market (GTM) strategies to effectively capture these emerging opportunities and respond to the rapidly changing market dynamics.
Key trends influencing the Dengue Testing market include the rapid adoption of digital technologies, the integration of sustainable practices, and the increasing importance of customer experience. These trends are not only driving growth but also creating new challenges for industry participants, who must adapt their GTM strategies to navigate regulatory changes, supply chain disruptions, and fluctuating economic conditions. Despite these challenges, the Dengue Testing market is poised for sustained growth, with emerging markets playing a critical role in the expansion of the industry.
Looking ahead, the Dengue Testing market is forecasted to continue its upward momentum through 2035, supported by ongoing investments in research and development, strategic partnerships, and mergers and acquisitions. Companies that can effectively tailor their GTM strategies to the evolving market landscape, innovate, and meet shifting consumer demands are likely to achieve sustained success. Dengue Testing market report provides a comprehensive analysis of the current market environment and offers valuable insights into the key drivers, challenges, and opportunities that will shape the industry's future over the next decade. This report offers a comprehensive analysis of market dynamics across various segments, regions, and countries, incorporating both qualitative and quantitative data. It covers the period from 2017 to 2035, providing a detailed examination of historical performance, current market conditions, and future projections.
Historical Analysis (2017-2024): The report presents a thorough review of market trends, performance metrics, and growth trajectories for the years 2017 through 2024. This historical perspective is crucial for understanding past market behavior and identifying patterns that influence current and future market dynamics.
Forecast and Projections (2026-2035) : Building on historical data, the report provides forward-looking insights, including market forecasts and growth projections from 2026 to 2035. It details anticipated market trends, emerging opportunities, and potential challenges across different segments, regions, and countries.
Compound Annual Growth Rate (CAGR): The report includes a precise calculation of the compound annual growth rate (CAGR) for the forecast period of 2026 to 2035. This metric will be instrumental in assessing the expected growth trajectory and the overall market potential during the forecast period.

Dengue Testing Market

The Dengue Testing Market encompasses diagnostic products and services used for detecting dengue virus in human blood, including enzyme-linked immunosorbent assays (ELISA), RT-PCR molecular tests, NS1 antigen tests, and rapid IgM/IgG detection kits. These diagnostics are implemented in clinical settings, centralized laboratories, point-of-care (POC) sites, and research facilities to support early and accurate disease identification, particularly in endemic tropical and subtropical regions.

The market includes both the testing platforms themselves such as automated ELISA readers and PCR instruments and consumables like cartridges, reagents, and rapid test strips. Its growth is closely tied to the increasing incidence and outbreak monitoring of dengue, technological innovation in POC diagnostics, and government-led public health initiatives aimed at enhancing surveillance and outbreak response capabilities.

What are the drivers of dengue testing market

• The increasing global incidence of dengue fever, particularly in tropical and subtropical regions, is the major driver in the dengue testing market. Climate change, urbanization, and increased international travel have expanded the habitat of Aedes mosquitoes, leading to frequent outbreaks and a surge in diagnostic demand.
• The growing emphasis on early diagnosis and timely intervention is further accelerating the adoption of dengue testing. Rapid, accurate detection helps in disease management, reducing progression to severe forms like dengue haemorrhagic fever or shock syndrome.
• Technological advancements including molecular assays, ELISA, and point of care rapid diagnostic tests are significantly enhancing diagnostic accuracy, speed, and accessibility. These innovations are especially valuable in remote or low resource settings, improving outbreak responsiveness.
• Supportive government and public health programs are boosting market expansion. Initiatives like Indias NVBDCP, WHO/Centers for Disease Control surveillance efforts, and donations of test kits by agencies like USAID are expanding testing infrastructure and awareness.
• Rising healthcare expenditure in developing regions is facilitating broader adoption of advanced diagnostic solutions. Growth in Asia-Pacific and Latin America, driven by funding for lab infrastructure and increased per capita healthcare spend, is fuelling demand for ELISA-based and RT-PCR tests.

What are the challenges and restraining factors of dengue testing market

• The high cost of advanced dengue diagnostic tests, particularly molecular PCR and ELISA methods, poses a significant barrier in endemic, resource-limited regions. These tests require expensive equipment and specialized reagents, making them unaffordable for many public healthcare systems.
• Even rapid diagnostic tests (RDTs), though less costly, often suffer from less accuracy, further limiting their appeal.
• In many endemic areas, limited healthcare infrastructure and access remain major obstacles. Rural and remote regions often lack diagnostic labs, cold chain capabilities, and trained personnel, leading to delays or missed diagnoses. This hampers early detection and effective outbreak control.
• Test reliability and regulatory inconsistency also constrain market penetration. RDTs often exhibit lower sensitivity and specificity, causing false positives or negatives. Varied regulatory approvals and lack of standardized protocols across countries delay the introduction of new tests and hinder consistent quality.
• The seasonal nature of dengue outbreaks and supply chain challenges create unpredictable demand. Testing needs surge during monsoon-related outbreaks, making inventory management difficult for manufacturers. Shortages of reagents and kits during peak seasons can disrupt diagnostics, as seen during Argentinas 2024 epidemic.

What are the regional trends of dengue testing market

North America is influenced by increasing traveller-related cases and occasional local outbreaks, associated with warmer temperatures and shifting mosquito habitats. Adoption of advanced diagnostic technologies such as rapid antigen tests, ELISA, and molecular assays is on the rise to support early detection and efficient case management. Countries like the U.S., Canada, and Mexico are investing in surveillance networks, climate-based vector forecasting, and health awareness programs to strengthen epidemic response.

Europe is seeing rising imported cases and sporadic local transmission linked to climate change. Health systems are adopting ELISA and molecular diagnostic platforms to support screening for travellers and public health monitoring. Southern European countries are integrating dengue testing into hospital and lab workflows, with investments in testing infrastructure and advanced diagnostic accuracy.

Asia Pacific dominates the market, driven by widespread endemicity in countries such as India, Indonesia, Thailand, and the Philippines. Tropical climates, urbanization, and frequent outbreaks significantly boost demand for diagnostic tests. National dengue control programs and enhanced lab infrastructure are supporting both centralized ELISA/RT-PCR setups and point-of-care rapid tests in rural and urban areas. Innovation in kit development and local manufacturing is helping meet urgent diagnostic needs.

Latin America is the fastest-growing region, reflecting record-high outbreaks including over 13 million suspected cases in early 2024. Countries such as Brazil, Argentina, Mexico, and Colombia are expanding diagnostic capacity via public health programs, surveillance systems, and widespread distribution of rapid test kits. National efforts to improve vector control and disease preparedness are increasing demand for ELISA, lateral flow, and molecular assays.

Middle East & Africa are experiencing rising mosquito activity linked to climate change. Countries like Saudi Arabia, UAE, Kenya, and Nigeria are strengthening diagnostic infrastructure through government and private sector investment. The region is seeing increased deployment of ELISA and PCR tests, along with point-of-care kits aimed at outbreak control. Efforts to build up surveillance and testing networks are accelerating dengue preparedness.

Country-Wise Outlook:

• United States: Rising dengue cases and strengthened public health mandates are driving market demand. The CDC has made dengue a notifiable disease, with cases reported in Florida, Texas, and other southern states. Increased mobility and climate-driven mosquito expansion have prompted adoption of NS1 antigen detection and multiplex RT-PCR tests. The CDC recommends these for differential diagnosis in suspected cases, especially where dengue co-circulates with Zika and chikungunya.
• Germany: A surge in travel-related dengue infections has increased diagnostic demand. The Robert Koch Institute reported 36 confirmed cases from travellers returning from Egypt in 2023, compared to zero to eight in previous years. Hospitals and travel clinics are expanding NS1 antigen and RT-PCR testing, supported by public health guidelines recommending proactive screening among febrile returning travellers.
• Japan: Climate change has expanded Aedes albopictus mosquito habitats northward, increasing dengue transmission risk. Health authorities have strengthened testing infrastructure, ensuring NS1 antigen and RT-PCR assays are widely available year-round for rapid detection and outbreak control.

Competitive Analysis:

The dengue testing market is highly competitive, with ELISA-based assays maintaining 45% share due to high accuracy in detecting NS1 antigens and IgM/IgG antibodies. Companies are improving serotype differentiation and automating workflows. Rapid diagnostic tests (RDTs) and RT-PCR methods are gaining traction with multiplex platforms detecting dengue alongside Zika and chikungunya.

Competition is driven by R&D capabilities, regulatory compliance, and speed to market. Major players like Abbott, Roche, Thermo Fisher, Bio-Rad, and SD Biosensor are expanding offerings in ELISA, RT-PCR, and lateral-flow formats. Price competitiveness is key in emerging markets, with centralized ELISA and RT-PCR labs dominating revenue (~60%) but POC and home testing growing fastest. Innovations like Abbotts SD BIOLINE Dengue Duo and app-enabled self-tests are boosting adoption.

Asia-Pacific leads in both volume (60%) and growth (511% CAGR) due to high local burden and climate change impacts. Regional manufacturers focus on localized serotypes, cost-effective distribution, and government partnerships. Integrated POC platforms combining diagnostics with mHealth connectivity and public-health data reporting are emerging as competitive differentiators.

Key players

Abbott Laboratories, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, Danaher Corporation, Quest Diagnostics Incorporated, QuidelOrtho Corporation, ARKRAY Inc., bioMerieux SA, InBios International Inc., Meridian Bioscience Inc., SD Biosensor Inc., GenBody Inc., and NovaTec Immundiagnostica GmbH.

Recent Developments:

• In August 2024, J Mitra & Company launched Indias first Dengue NS1 Antigen self-test kit for home use, providing rapid (20-minute) detection across all four dengue serotypes to improve accessibility and outbreak response.
• In October 2024, Abbott Laboratories introduced an advanced dengue IgG/IgM rapid diagnostic test, delivering highly accurate results in under 15 minutes, designed for large-scale usage in resource-limited outbreak regions.
• In September 2024, World Health Organization launched a Global Strategic Preparedness, Readiness, and Response Plan (SPRP) focused on dengue and other Aedes-borne arboviruses, bolstering surveillance systems and diagnostic readiness internationally.

MENAFN09102025007836016821ID1110172443